FDA Approval of RSV Drug Gives Infants and Toddlers Long-Lasting Protection – MedCity News

AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.

Read the full article here

Related Articles